As of March 1, 2024, an article processing charge (APC) of USD 400 + 20% VAT will be requested for newly submitted research, review, meta-analysis articles to the Anatolian Journal of Cardiology if they are accepted for publication.
The Anatolian Journal of Cardiology
Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism? [Anatol J Cardiol]
Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?
Marija Vavlukis, Irina Kotlar, Hajber Taravari, Lidija Poposka, Sasko KedevUniversity Clinic of Cardiology, Medical Faculty, University Ss' Cyril and Methodius; Skopje-Republic of Macedonia
Marija Vavlukis, Irina Kotlar, Hajber Taravari, Lidija Poposka, Sasko Kedev. Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?. Anatol J Cardiol. 2017; 18(1): 77-79
Corresponding Author: Marija Vavlukis, Macedonia Manuscript Language: English